MMM — Medicare/Medicaid
H.R.7148Consolidated AppropriationsMaking further consolidated appropriations for the fiscal year ending September 30, 2026 S.2497Fair Billing ActLegislation to ensure fair billing practice for items and services furnished by off-campus hospital locations Legislation to align Medicare reimbursement rates across different settings-such as hospital outpatient departments (HOPDs), ambulatory surgical centers (ASCs), and physician offices-for services that can safely be performed in lower-cost settings. Pay PCPs Acta bill to task the Centers for Medicare & Medicaid Services (CMS) with establishing hybrid payments to reward primary care providers who provide the best care to their patients S.1105No UPCODE ActA bill to amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
S.527Prescription Pricing for the People Act of 2025To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. S.1040Drug Competition Enhancement ActTo amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S.1041Affordable Prescriptions for Patients ActTo amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1097Interagency Patent Coordination and Improvement Act of 2025To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. S.1095Stop STALLING ActTo enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. S.1096Preserve Access to Affordable Generics and BiosimilarsTo prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products S.2276/3269ETHIC ActTo address patent thickets.
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
H.R.247/S.46Health Care Affordability ActTo amend the Internal Revenue Code of 1986 to expand eligibility for the refundable credit for coverage under a qualified health plan. HR6248Healthy Competition for Better Care Actlegislation to ban anticompetitive terms in insurer-provider contracts S. 2355Patients Deserve Price Tags ActLegislation to strengthen and codify federal hospital and insurer transparency rules to ensure the publication of prices in dollars and cents
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE